As loss of TP53 is known to herald a poor prognosis in MCL (152), and since olaparib synergized with the BTK inhibitor, ibrutinib, in MCL cell lines (153), these data provide promising grounds for the design of a PARP inhibitor-BTK combination in this high risk subset of MCL. This evidence concerns the gene TP53 and mantle cell lymphoma.